Niacin Alternatives for Dyslipidemia: Fool's Gold or Gold Mine? Part II: Novel Niacin Mimetics - Test2 - elhamkhani - TriplyDB

Niacin Alternatives for Dyslipidemia: Fool's Gold or Gold Mine? Part II: Novel Niacin Mimetics

Niacin Alternatives for Dyslipidemia: Fool's Gold or Gold Mine? Part II: Novel Niacin Mimetics

http://www.wikidata.org/entity/Q26765137

about

Nicotinic acid inhibits glioma invasion by facilitating Snail1 degradation Pleiotropic effects of niacin: Current possibilities for its clinical use.Measuring niacin-associated skin toxicity (NASTy) stigmata along with symptoms to aid development of niacin mimetics.CAT-2003: A novel sterol regulatory element-binding protein inhibitor that reduces steatohepatitis, plasma lipids, and atherosclerosis in apolipoprotein E*3-Leiden mice.Natural approaches in metabolic syndrome management.

P2860

Q37679063-DA8F5B10-28A9-430C-AB9E-EB2659D2E532 Q38810790-8660420E-D401-4B5F-9650-CB1E1A7BB44B Q40365888-9BD133A8-7454-4D1C-A5EF-A16F5F35C910 Q51754950-29760D83-CCFF-498B-A727-A5210E90835F Q51758644-6A387C9D-7B58-47F0-B8C8-E2252654FCCB

P2860

Niacin Alternatives for Dyslipidemia: Fool's Gold or Gold Mine? Part II: Novel Niacin Mimetics

http://www.wikidata.org/entity/Q26765137

description

2016 nî lūn-bûn

@nan

2016 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Niacin Alternatives for Dyslip ...... Part II: Novel Niacin Mimetics

@ast

Niacin Alternatives for Dyslip ...... Part II: Novel Niacin Mimetics

@en

Niacin Alternatives for Dyslip ...... Part II: Novel Niacin Mimetics

@nl

type

label

Niacin Alternatives for Dyslip ...... Part II: Novel Niacin Mimetics

@ast

Niacin Alternatives for Dyslip ...... Part II: Novel Niacin Mimetics

@en

Niacin Alternatives for Dyslip ...... Part II: Novel Niacin Mimetics

@nl

prefLabel

Niacin Alternatives for Dyslip ...... Part II: Novel Niacin Mimetics

@ast

Niacin Alternatives for Dyslip ...... Part II: Novel Niacin Mimetics

@en

Niacin Alternatives for Dyslip ...... Part II: Novel Niacin Mimetics

@nl

P1433

Q26765137-0DF61A98-CABE-447C-A0D3-22EAF0D377FF

P1476

Q26765137-797CAC1F-178B-4E2E-9682-5195AF28AA9E

P2093

Q26765137-53753722-63FD-40CF-9FE4-2298EEAB9F40

Q26765137-F60BC36A-BFE6-4246-98AC-2D63EAEC64E4

P275

Q26765137-B996EF09-F4D0-4005-8D97-6DF993371B17

P2860

Q26765137-0EFE415C-D450-4348-B30B-095FBAB4C2ED

Q26765137-11F5AA6D-756A-4599-8503-FA6744DB6F02

Q26765137-12F2C844-4222-4665-8815-083219CDAA5C

Q26765137-17329FFA-1C67-4209-8AE7-D20263983F36

Q26765137-20762229-FDFC-489B-9961-E4335D53D17A

Q26765137-2401928C-96B6-40FF-A2E6-0AC7454CFFEC

Q26765137-299443D8-94C8-435D-8CEE-57A5F60C0AC7

Q26765137-2F2D4AEF-D755-4109-B4E6-955D695843DB

Q26765137-3481EE3E-5201-4990-883F-382D60EB5610

Q26765137-3600C991-DA43-47D5-95BA-C7A7B2CC5726

P2888

Q26765137-8429F697-6355-4338-8F04-75F688BC7066

P304

Q26765137-A7527F57-E8DA-47C2-94F5-1B5A916B5A71

P31

Q26765137-6C6A1BA1-7152-44BF-A13A-B64401979523

Q26765137-ACEFB2E1-C10F-4D03-B0A8-43176BAC9D4B

P3181

Q26765137-3B60812D-1BD9-44B1-9122-C1E195D74B2B

P356

Q26765137-A38FF2EC-F074-470A-8B94-8138F289AA2C

P407

Q26765137-0A281099-EB66-43C9-87A3-FBBB1285CB8F

P433

Q26765137-0B48E9F6-BB94-4A0C-81AA-E0D8F0066F41

P478

Q26765137-CEE8AF63-B828-48BF-B41F-110EF4EC4F45

P5008

Q26765137-FAE255FC-571E-4F0C-86A4-55A610CAFFBA

P577

Q26765137-98667CD5-5100-4A4C-95D7-56ED2F8AFEA8

Q26765137-D1898A6D-7B38-4F6A-967D-AC732748711B

P5875

Q26765137-963E82FF-BC7D-42E9-989C-ADBA56C73C59

P6179

Q26765137-5F20D5EE-DC92-49B9-B6A6-562A0B6E7983

P698

Q26765137-ABA3ACA8-C114-4B4B-B0E3-A1E427CA77C6

P921

Q26765137-0A48CC51-C0CF-47CC-A197-6B45EF458AB8

Q26765137-AC2A5177-9ADF-4E98-88A0-52966FEDF64A

Q26765137-CD0A6142-DB60-42E1-BBCD-714D4E4346B6

Q26765137-D94D7591-01F6-445B-92C7-1EF2683B5EF3

Q26765137-E72500E1-DD06-4CD7-A2DE-ADE88343620D

P932

Q26765137-4F823C45-1FA4-4954-BA5C-AADDD3C518B1

P3181

P356

S11883-016-0570-9

P1433

Current Atherosclerosis Reports

P1476

Niacin Alternatives for Dyslip ...... Part II: Novel Niacin Mimetics

@en

P2093

Harsh Goel

http://www.w3.org/2001/XMLSchema#string

Richard L Dunbar

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 4.0 International

P2860

Regulation of hepatic ApoC3 expression by PGC-1β mediates hypolipidemic effect of nicotinic acid

Nicotinic acid- and monomethyl fumarate-induced flushing involves GPR109A expressed by keratinocytes and COX-2-dependent prostanoid formation in mice

beta-Arrestin1 mediates nicotinic acid-induced flushing, but not its antilipolytic effect, in mice

Niacin Alternatives for Dyslipidemia: Fool's Gold or Gold Mine? Part I: Alternative Niacin Regimens.

Molecular identification of nicotinic acid receptor

Isosorbide-based aspirin prodrugs. II. Hydrolysis kinetics of isosorbide diaspirinate

Molecular identification of high and low affinity receptors for nicotinic acid

PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect

Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy

Characterization of a G protein-coupled receptor for nicotinic acid.

P2888

s11883-016-0570-9

P304

17

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

4952294

http://www.w3.org/2001/XMLSchema#string

P356

10.1007/S11883-016-0570-9

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

18

http://www.w3.org/2001/XMLSchema#string

P5008

P577

2016-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

296480135

http://www.w3.org/2001/XMLSchema#string

P6179

1030731648

http://www.w3.org/2001/XMLSchema#string

P698

26932224

http://www.w3.org/2001/XMLSchema#string

P921

lipid metabolism disorder

heterocyclic compound

mechanism of action

manufactured product

P932

4773474

http://www.w3.org/2001/XMLSchema#string